CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionOperating margin is 38%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.74%
Annual Rate
CNY 0.45Paid unknown
Payout Ratio
84.9%Moderate
Last Ex-Dividend
Jun 16, 2026
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
7.70BCNY1.15B · vs all stocks (USD)
Trailing P/E
84.45xvs Biotechnology peers
Revenue (TTM)
323.87MCNY48.16M · vs all stocks (USD)
Profit Margin
27.73%vs Biotechnology peers
Beta
1.10xvs all stocks
52-Week Change
70.70%vs all stocks
Forward Annual Dividend Yield
0.74%vs all stocks
Market Capitalization
7.70BCNY1.15B · vs all stocks (USD)
Enterprise Value
5.63BCNY837.75M · vs all stocks (USD)
Trailing P/E
84.45xvs Biotechnology peers
Forward P/E
55.13xvs Biotechnology peers
Price to Sales (TTM)
23.58xvs Biotechnology peers
Price to Book (MRQ)
3.59xvs Biotechnology peers
Enterprise to Revenue
17.39xvs Biotechnology peers
Enterprise to EBITDA
61.30xvs Biotechnology peers
Gross Margin
76.36%vs Biotechnology peers
Profit Margin
27.73%vs Biotechnology peers
Operating Margin
37.99%vs Biotechnology peers
Return on Assets (TTM)
1.90%vs Biotechnology peers
Return on Equity (TTM)
4.32%vs Biotechnology peers
Revenue (TTM)
323.87MCNY48.16M · vs all stocks (USD)
Revenue per Share (TTM)
2.38CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-47.40%vs Biotechnology peers
Gross Profit (TTM)
237.00MCNY35.24M · vs all stocks (USD)
EBITDA (TTM)
188.21MCNY27.99M · vs all stocks (USD)
Net Income (TTM)
89.82MCNY13.36M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-57.40%vs Biotechnology peers
Operating Cash Flow (TTM)
48.49MCNY7.21M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
9.06MCNY1.35M · vs all stocks (USD)
Forward Annual Dividend Rate
0.4500CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
0.74%vs all stocks
Trailing Annual Dividend Rate
0.4500CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.74%vs all stocks
Payout Ratio
84.85%vs Biotechnology peers
Revenue
422.03MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
91.68MCNYFY2025 · Dec 31, 2025Gross Profit
330.35MCNYFY2025 · Dec 31, 2025Operating Income
128.89MCNY19.17M · vs all stocks (USD)
Pre-tax Income
159.66MCNYFY2025 · Dec 31, 2025Income Tax Expense
15.19MCNYFY2025 · Dec 31, 2025Net Income
144.47MCNYFY2025 · Dec 31, 2025EBIT
159.82MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
177.89MCNYFY2025 · Dec 31, 2025Research & Development
94.91MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
45.94MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
156.05KCNYFY2025 · Dec 31, 2025EPS (Basic)
1.06CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.06CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
136.30MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
136.30MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
144.47MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
172.77MCNYFY2025 · Dec 31, 2025Free Cash Flow
141.79MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
567.09MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
144.47MCNYFY2025 · Dec 31, 2025Other Non-cash Items
10.77MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
37.12MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-19.59MCNYFY2025 · Dec 31, 2025Capital Expenditures
-30.98MCNYFY2025 · Dec 31, 2025Net Acquisitions
-4.00MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.31BCNYFY2025 · Dec 31, 2025Sale of Investments
3.52BCNYFY2025 · Dec 31, 2025Other Investing Activity
500.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
168.71MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-75.23MCNYFY2025 · Dec 31, 2025Other Financing Charges
-25.55MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-100.79MCNYFY2025 · Dec 31, 2025Shares Outstanding
136.98MSharesUpdated Aug 21, 2026Float Shares
105.41MSharesUpdated Aug 21, 2026% Held by Insiders
53.75%vs all stocks
% Held by Institutions
2.41%vs all stocks
Total Cash (MRQ)
1.89BCNY281.60M · vs all stocks (USD)
Total Cash per Share (MRQ)
14.04CNYUpdated Aug 21, 2026Total Debt (MRQ)
9.34MCNY1.39M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0045xvs Biotechnology peers
Current Ratio (MRQ)
15.58xvs Biotechnology peers
Book Value per Share (MRQ)
15.54CNYUpdated Aug 21, 2026Total Assets
2.28BCNY338.37M · vs all stocks (USD)
Total Current Assets
2.03BCNYFY2025 · Dec 31, 2025Total Liabilities
223.32MCNYFY2025 · Dec 31, 2025Total Non-current Assets
248.24MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
9.72MCNYFY2025 · Dec 31, 2025Total Current Liabilities
213.60MCNYFY2025 · Dec 31, 2025Cash
564.04MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.05MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
567.09MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.38BCNYFY2025 · Dec 31, 2025Accounts Receivable
12.00MCNYFY2025 · Dec 31, 2025Inventory
57.18MCNYFY2025 · Dec 31, 2025Accounts Payable
79.12MCNYFY2025 · Dec 31, 2025Short-term Debt
3.84MCNYFY2025 · Dec 31, 2025Other Current Liabilities
10.80MCNYFY2025 · Dec 31, 2025Long-term Debt
3.95MCNYFY2025 · Dec 31, 2025Common Stock (Book)
136.98MCNYFY2025 · Dec 31, 2025Retained Earnings
872.16MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.05BCNY305.16M · vs all stocks (USD)
Treasury Stock
78.01MCNYFY2025 · Dec 31, 202552-Week Low
29.99CNYUpdated Aug 21, 202652-Week High
73.58CNYUpdated Aug 21, 202652-Week Change
70.70%vs all stocks
Beta
1.10xvs all stocks
50-Day MA
58.76CNYUpdated Aug 21, 2026200-Day MA
44.38CNYUpdated Aug 21, 2026Avg 10-Day Volume
3.30MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.32MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.6600CNYUpdated Aug 21, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 38%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.38Industry median: -0.24Industry P95: 0.38Peers compared: 197
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 23.58Revenue Growth YoY: -0.47
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alvotech S.A.
Tier 1ProductionApproval-Gated PipelineRule
MeiraGTx Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shantou Institute of Ultrasonic Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SSY Group Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gen Ilac ve Saglik Urunleri A.S.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eton Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Savara Inc.
Tier 1ProductionApproval-Gated PipelineRule
BioGaia AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
National Aluminium Company Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
United States Lime & Minerals Inc.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Texas Pacific Land Corporation
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels